Organogenesis Holdings (ORGO) Receivables (2017 - 2026)

Organogenesis Holdings' Receivables history runs 10 years deep, the most recent figure standing at $131.3 million for Q1 2026.

• In Q1 2026, Receivables rose 27.05% year-over-year to $131.3 million; the TTM figure through Mar 2026 stood at $131.3 million (up 27.05% YoY), while the FY2025 annual figure was $217.5 million, up 82.06% from the prior year.
• Receivables was $131.3 million for Q1 2026 at Organogenesis Holdings, down from $217.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $217.5 million in Q4 2025 to a low of $79.5 million in Q1 2022.
• Historically, Receivables has averaged $113.0 million across 5 years, with a median of $100.3 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Receivables retreated 14.42% in 2023, then soared 82.06% in 2025.
• A 5-year view of Receivables shows it stood at $95.8 million in 2022, then decreased by 14.42% to $82.0 million in 2023, then soared by 45.66% to $119.4 million in 2024, then soared by 82.06% to $217.5 million in 2025, then sank by 39.63% to $131.3 million in 2026.
• The last three Receivables figures came in at $131.3 million (Q1 2026), $217.5 million (Q4 2025), and $168.8 million (Q3 2025), per Business Quant data.